Concepedia
Statistics
Publications
3
Citations
65
H-Index
Active since
2016
Affiliations
University of Toronto(Current)
National Taiwan University Hospital
University of California, Los Angeles
Prince of Wales Hospital
Kindai University
P.A. Watson is an author at University of Toronto specializing in oncology, pembrolizumab therapy, and checkpoint inhibitor therapy.
Publications per year
2016–2017
KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
Richard S. Finn, Stephen L. Chan, Andrew X. Zhu et al. · Journal of Clinical Oncology · 2017 · 43 citations
Medicine, Oncology, Pharmacotherapy +17
Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
Richard S. Finn, Stephen L. Chan, Andrew X. Zhu et al. · Annals of Oncology · 2016 · 11 citations · Full text
Medicine, Oncology, Pharmacology +13
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
Andrew X. Zhu, Jennifer J. Knox, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2017 · 11 citations
Pharmacy, Oncology, Pharmacotherapy +17
1–3 of 3